Literature DB >> 16825092

Predictive factors for chronic renal failure one year after orthotopic liver transplantation.

Joelle Guitard1, David Ribes, Nassim Kamar, Fabrice Muscari, Olivier Cointault, Laurence Lavayssière, Bertrand Suc, Laure Esposito, Jean-Marie Peron, Lionel Rostaing.   

Abstract

Chronic renal failure (CRF) is increasingly prevalent in solid-organ-transplant patients. This is in part related to the long-term use of calcineurin inhibitor (CNI) agents. However, in orthotopic liver-transplant (OLT) patients, the effects of superimposed hepatitis C virus (HCV)-related renal lesions could also be a factor. The aim of this cohort study (February 2000 to September, 2003) was to identify the predictive factors at one year post-transplantation for CRF in OLT patients associated with induction therapies. CRF was defined as having a creatinine clearance (CC) lower than 60 mL/min. Of the 97 transplants performed during that period, 72 were still functioning after one year. Of these, 33 patients (45.8%) had CRF. In univariate analysis, the predicting factors for CRF were recipient sex (female), initial liver disease (HCV-related cirrhosis), pre-transplant CC (<80 mL/mn), and post-transplant serum creatinine >130 micromol/L at day 3 and months (M) 1, 3, and 6. In multivariate analysis, the independent predictive factors for CRF included female sex [OR: 11.5 (2.3-58.3); p = 0.003], HCV infection [OR: 5.01 (1.1-22.7); p = 0.03], pre-OLT CC <80 mL/mn [OR: 5.4 (1.2-23.7); p = 0.025], and serum creatinine at M6 greater than 130 micromol/L [OR: 19.6 (3.7-102.5); p = 0.0004]. Among all of the predictive factors for post-OLT CRF, only one is modifiable: post-transplant serum creatinine, which could be, to some extent, related to the long-term use of CNIs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825092     DOI: 10.1080/08860220600683607

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  5 in total

1.  Involvement of indirectly allostimulated CD4+CD43highCD45RO+ T cell proliferation in the development of chronic allograft nephropathy.

Authors:  Yu-Mee Wee; Joo-Hee Jung; Yang-Hee Kim; Monica-Y Choi; Young-Hoon Kim; Do-Sook Choi; Myung-Hwan Cho; Duck-Jong Han
Journal:  Exp Biol Med (Maywood)       Date:  2015-09-07

Review 2.  Pre-transplant kidney function predicts chronic kidney disease after liver transplant: meta-analysis of observational studies.

Authors:  Fabrizio Fabrizi; Vivek Dixit; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

3.  Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation.

Authors:  Lisa B VanWagner; Samantha Montag; Lihui Zhao; Norrina B Allen; Donald M Lloyd-Jones; Arighno Das; Anton I Skaro; Samuel Hohmann; John J Friedewald; Josh Levitsky
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

4.  Discovery and Validation of a Biomarker Model (PRESERVE) Predictive of Renal Outcomes After Liver Transplantation.

Authors:  Josh Levitsky; Sumeet K Asrani; Goran Klintmalm; Thomas Schiano; Adyr Moss; Kenneth Chavin; Charles Miller; Kexin Guo; Lihui Zhao; Linda W Jennings; Merideth Brown; Brian Armstrong; Michael Abecassis
Journal:  Hepatology       Date:  2020-01-28       Impact factor: 17.425

5.  Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction.

Authors:  Tiong Yeng Lim; Mark J McPhail; Amar Shah; Sara Mahgoub; Jeremy Nayagam; Matthew Cramp; William Bernal; Krish Menon; Wayel Jassem; Deepak Joshi; Michael A Heneghan; Kosh Agarwal; Nigel D Heaton; Abid Suddle; John G O'Grady; Varuna R Aluvihare
Journal:  Transplant Direct       Date:  2020-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.